HIV Scientific Papers
Achieving virological control in pan-resistant HIV-1 infection: A case series
2022
Diana Canetti, Camilla Muccini, Vincenzo Spagnuolo, Laura Galli, Andrea Poli, Nicola Gianotti, Marcello Feasi, and Antonella Castagna,
The Lancet Vol 77 Month March, 2022 11
HIV-1 Non-Group M Phenotypic Susceptibility to Ibalizumab
2022
L. Poisson-Arnaud, Quentin le Hingrat, JC Plantier and E Alessandri-Gradt
IV Push Administration of Ibalizumab: Pharmacokinetics, Safety, and Efficacy
2022
Edwin DeJesus, Gary Richmond, Mezgebe Berhe, Anthony Mills, Tanya Schreibman, Charlotte-Paige Rolle, Kuei-Ling Kuo, Mohammed Zogheib, Olivia G. Goss, R. Brandon Cash, YingAn Lai, Martin Markowitz, Pedro M. Mesquita
Efficacy, pharmacokinetics, and safety over 48 weeks with ibalizumab-based therapy in treatment-experienced adults infected with HIV-1: a phase 2a study.
2021
J Acquir Immune Defic Syndr.
Gathe JC, Hardwicke RL, Garcia F, et al.
86(4):482-489.
Assessment of genotypic patterns associated with HIV-1 sensitivity to ibalizumab [abstract].
2020
Reviews in Antiviral Therapy & Infectious Diseases.
Jullien H, Leonard M, Cash RB, et al.
7:27. Proceedings of the European Meeting on HIV & Hepatitis 2020.